Stem Cell Transplantation for Ovarian Cancer Patient with Associated Myelodysplasia After Maintenance Therapy with Olaparib: A Case Report

Zeyar Linn,1 Zhongyi Gu,1 Libing Wang,2 Shengyun Cai1 1Department of Obstetrics and Gynecology, The First Affiliated Hospital of Naval Medical University (Changhai Hospital), Naval Medical University, Shanghai, People’s Republic of China; 2Department of Hematology, The First Affiliated Hospital of N...

Full description

Saved in:
Bibliographic Details
Main Authors: Linn Z, Gu Z, Wang L, Cai S
Format: Article
Language:English
Published: Dove Medical Press 2025-02-01
Series:International Medical Case Reports Journal
Subjects:
Online Access:https://www.dovepress.com/stem-cell-transplantation-for-ovarian-cancer-patient-with-associated-m-peer-reviewed-fulltext-article-IMCRJ
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1823857977793183744
author Linn Z
Gu Z
Wang L
Cai S
author_facet Linn Z
Gu Z
Wang L
Cai S
author_sort Linn Z
collection DOAJ
description Zeyar Linn,1 Zhongyi Gu,1 Libing Wang,2 Shengyun Cai1 1Department of Obstetrics and Gynecology, The First Affiliated Hospital of Naval Medical University (Changhai Hospital), Naval Medical University, Shanghai, People’s Republic of China; 2Department of Hematology, The First Affiliated Hospital of Naval Medical University (Changhai Hospital), Naval Medical University, Shanghai, People’s Republic of ChinaCorrespondence: Shengyun Cai, Department of Obstetrics and Gynecology, The First Affiliated Hospital of Naval Medical University (Changhai Hospital), Naval Medical University, 168 Changhai Road, Shanghai, 200433, People’s Republic of China, Email [email protected]: Ovarian cancer remains a significant cause of morbidity and mortality in women worldwide. Olaparib, a poly ADP-ribose polymerase (PARP) inhibitor, has been shown in studies to increase the time that people with cancer do not get worse. However, reports have indicated rare adverse effects, like myelodysplastic syndrome (MDS). In this report, we highlight the case of a 42-year-old female patient who was diagnosed with ovarian endometrioid carcinoma, FIGO Stage IIB. Following surgery and chemotherapy, the patient commenced maintenance therapy with Olaparib. After two years, she experienced abnormal blood test results, which ultimately led to a diagnosis of myelodysplastic syndrome (MDS), confirmed through a bone marrow biopsy. Despite initial obstacles, the patient underwent stem cell transplantation as a treatment for MDS. After undergoing stem cell transplantation, the patient experienced a notable improvement in their condition. Upon reevaluation, the transplantation proved successful as it resolved the abnormalities related to MDS. Furthermore, the ovarian cancer status showed a positive response, with no signs of disease progression during the follow-up period. This particular case emphasizes the importance of being vigilant for uncommon adverse effects, such as MDS, in ovarian cancer patients undergoing Olaparib maintenance therapy. Early diagnosis and treatment, which may include stem cell transplantation, can lead to favorable results, not only in managing MDS but also in possibly slowing down the progression of ovarian cancer that is causing it. Additional research is necessary to understand the risk factors and the most effective management approaches for these complications in this specific group of patients.Keywords: stem cell transplantation, ovarian cancer, myelodysplasia, olaparib, case report
format Article
id doaj-art-605f72dd4ce64e9d98dfdf111e26224c
institution Kabale University
issn 1179-142X
language English
publishDate 2025-02-01
publisher Dove Medical Press
record_format Article
series International Medical Case Reports Journal
spelling doaj-art-605f72dd4ce64e9d98dfdf111e26224c2025-02-11T17:30:56ZengDove Medical PressInternational Medical Case Reports Journal1179-142X2025-02-01Volume 18241248100061Stem Cell Transplantation for Ovarian Cancer Patient with Associated Myelodysplasia After Maintenance Therapy with Olaparib: A Case ReportLinn ZGu ZWang LCai SZeyar Linn,1 Zhongyi Gu,1 Libing Wang,2 Shengyun Cai1 1Department of Obstetrics and Gynecology, The First Affiliated Hospital of Naval Medical University (Changhai Hospital), Naval Medical University, Shanghai, People’s Republic of China; 2Department of Hematology, The First Affiliated Hospital of Naval Medical University (Changhai Hospital), Naval Medical University, Shanghai, People’s Republic of ChinaCorrespondence: Shengyun Cai, Department of Obstetrics and Gynecology, The First Affiliated Hospital of Naval Medical University (Changhai Hospital), Naval Medical University, 168 Changhai Road, Shanghai, 200433, People’s Republic of China, Email [email protected]: Ovarian cancer remains a significant cause of morbidity and mortality in women worldwide. Olaparib, a poly ADP-ribose polymerase (PARP) inhibitor, has been shown in studies to increase the time that people with cancer do not get worse. However, reports have indicated rare adverse effects, like myelodysplastic syndrome (MDS). In this report, we highlight the case of a 42-year-old female patient who was diagnosed with ovarian endometrioid carcinoma, FIGO Stage IIB. Following surgery and chemotherapy, the patient commenced maintenance therapy with Olaparib. After two years, she experienced abnormal blood test results, which ultimately led to a diagnosis of myelodysplastic syndrome (MDS), confirmed through a bone marrow biopsy. Despite initial obstacles, the patient underwent stem cell transplantation as a treatment for MDS. After undergoing stem cell transplantation, the patient experienced a notable improvement in their condition. Upon reevaluation, the transplantation proved successful as it resolved the abnormalities related to MDS. Furthermore, the ovarian cancer status showed a positive response, with no signs of disease progression during the follow-up period. This particular case emphasizes the importance of being vigilant for uncommon adverse effects, such as MDS, in ovarian cancer patients undergoing Olaparib maintenance therapy. Early diagnosis and treatment, which may include stem cell transplantation, can lead to favorable results, not only in managing MDS but also in possibly slowing down the progression of ovarian cancer that is causing it. Additional research is necessary to understand the risk factors and the most effective management approaches for these complications in this specific group of patients.Keywords: stem cell transplantation, ovarian cancer, myelodysplasia, olaparib, case reporthttps://www.dovepress.com/stem-cell-transplantation-for-ovarian-cancer-patient-with-associated-m-peer-reviewed-fulltext-article-IMCRJstem cell transplantationovarian cancermyelodysplasiaolaparibcase report.
spellingShingle Linn Z
Gu Z
Wang L
Cai S
Stem Cell Transplantation for Ovarian Cancer Patient with Associated Myelodysplasia After Maintenance Therapy with Olaparib: A Case Report
International Medical Case Reports Journal
stem cell transplantation
ovarian cancer
myelodysplasia
olaparib
case report.
title Stem Cell Transplantation for Ovarian Cancer Patient with Associated Myelodysplasia After Maintenance Therapy with Olaparib: A Case Report
title_full Stem Cell Transplantation for Ovarian Cancer Patient with Associated Myelodysplasia After Maintenance Therapy with Olaparib: A Case Report
title_fullStr Stem Cell Transplantation for Ovarian Cancer Patient with Associated Myelodysplasia After Maintenance Therapy with Olaparib: A Case Report
title_full_unstemmed Stem Cell Transplantation for Ovarian Cancer Patient with Associated Myelodysplasia After Maintenance Therapy with Olaparib: A Case Report
title_short Stem Cell Transplantation for Ovarian Cancer Patient with Associated Myelodysplasia After Maintenance Therapy with Olaparib: A Case Report
title_sort stem cell transplantation for ovarian cancer patient with associated myelodysplasia after maintenance therapy with olaparib a case report
topic stem cell transplantation
ovarian cancer
myelodysplasia
olaparib
case report.
url https://www.dovepress.com/stem-cell-transplantation-for-ovarian-cancer-patient-with-associated-m-peer-reviewed-fulltext-article-IMCRJ
work_keys_str_mv AT linnz stemcelltransplantationforovariancancerpatientwithassociatedmyelodysplasiaaftermaintenancetherapywitholaparibacasereport
AT guz stemcelltransplantationforovariancancerpatientwithassociatedmyelodysplasiaaftermaintenancetherapywitholaparibacasereport
AT wangl stemcelltransplantationforovariancancerpatientwithassociatedmyelodysplasiaaftermaintenancetherapywitholaparibacasereport
AT cais stemcelltransplantationforovariancancerpatientwithassociatedmyelodysplasiaaftermaintenancetherapywitholaparibacasereport